M
Manli Wang
Researcher at Chinese Academy of Sciences
Publications - 115
Citations - 9312
Manli Wang is an academic researcher from Chinese Academy of Sciences. The author has contributed to research in topics: Virus & Medicine. The author has an hindex of 18, co-authored 89 publications receiving 7105 citations. Previous affiliations of Manli Wang include Wageningen University and Research Centre.
Papers
More filters
Journal ArticleDOI
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Manli Wang,Ruiyuan Cao,Leike Zhang,Xing-Lou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao +9 more
TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.
Journal ArticleDOI
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro
J.D. Liu,Ruiyuan Cao,Mingyue Xu,Xi Wang,Huanyu Zhang,Hengrui Hu,Yufeng Li,Zhihong Hu,Wu Zhong,Manli Wang +9 more
TL;DR: Evaluated the antiviral effect of HCQ against SARS-CoV-2 infection in comparison to CQ in vitro and concluded that CQ appears to be the drug of choice for large-scale use due to its availability, proven safety record, and a relatively low cost.
Journal ArticleDOI
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Xi Wang,Ruiyuan Cao,Huanyu Zhang,J.D. Liu,Mingyue Xu,Hengrui Hu,Yufeng Li,Lei Zhao,Wei Li,Xiulian Sun,Xing-Lou Yang,Zhengli Shi,Fei Deng,Zhihong Hu,Wu Zhong,Manli Wang +15 more
TL;DR: Six currently available and licensed anti-influenza drugs against SARS-CoV-2 are evaluated and it is suggested that arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate of COVID-19 patients.
Journal ArticleDOI
SARS-CoV-2 cell tropism and multiorgan infection
Journal ArticleDOI
Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Ruiyuan Cao,Hengrui Hu,Yufeng Li,Xi Wang,Mingyue Xu,Jia Liu,Huanyu Zhang,Yunzheng Yan,Lei Zhao,Wei Li,Tianhong Zhang,Xiao Dian,Xiaojia Guo,Yuexiang Li,Jingjing Yang,Zhihong Hu,Manli Wang,Wu Zhong +17 more
TL;DR: Evaluated anti-SARS-CoV-2 activities of nine artemisinin-related compounds in vitro and carried out a time-of-drug-addition assay to explore their antiviral mode of action; a pharmacokinetic prediction model was established to predict the therapeutic potential of selected compounds against COVID-19 and revealed lumefantrine showed therapeutic promise due to high plasma and lung drug concentrations after multiple dosing.